Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy, improving outcomes in the treatment of various malignancies. However, not all patients benefit to the same extend from ICI. Reliable tools to predict treatment response and outcome are missing. Soluble ur...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Oncol
Prif Awduron: Loosen, Sven H., Gorgulho, Joao, Jördens, Markus S., Schulze-Hagen, Maximilian, Beier, Fabian, Vucur, Mihael, Schneider, Anne T., Koppe, Christiane, Mertens, Alexander, Kather, Jakob N., Tacke, Frank, Keitel, Verena, Brümmendorf, Tim H., Roderburg, Christoph, Luedde, Tom
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2021
Pynciau:
Oncology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047604/
https://ncbi.nlm.nih.gov/pubmed/33869041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.646883
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg